These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Foscarnet versus ganciclovir in the management of cytomegalovirus disease in patients with AIDS. Minor JR Am J Hosp Pharm; 1991 Nov; 48(11):2478-9. PubMed ID: 1660675 [No Abstract] [Full Text] [Related]
6. [Cytomegalovirus infection in patients after lung transplantation]. Cerrina J; Le Roy Ladurie F Presse Med; 1992 Mar; 21(11):503-6. PubMed ID: 1315436 [No Abstract] [Full Text] [Related]
7. Sensitivity of cytomegalovirus to intravenous foscarnet treatment. Akesson-Johansson A; Lernestedt JO; Ringdén O; Lönnqvist B; Wahren B Bone Marrow Transplant; 1986 Dec; 1(2):215-20. PubMed ID: 2844334 [TBL] [Abstract][Full Text] [Related]
8. Foscarnet prophylaxis in marrow transplant recipients. Ringden O; Lonnqvist B; Aschan J; Sundberg B Bone Marrow Transplant; 1989 Nov; 4(6):713. PubMed ID: 2555006 [No Abstract] [Full Text] [Related]
10. Problems in the management of cytomegalovirus infection in patients with AIDS. Connolly GM; Nelson MR; Barton SE; Gazzard BG Int J STD AIDS; 1991; 2(6):405-10. PubMed ID: 1664242 [No Abstract] [Full Text] [Related]
11. Therapy of cytomegalovirus infections with ganciclovir: a critical appraisal. Collier AC; Corey L Curr Clin Top Infect Dis; 1992; 12():309-28. PubMed ID: 1322676 [No Abstract] [Full Text] [Related]
12. [Treatment of cytomegalovirus infections in immunosuppressed patients]. Michon C; Girard PM; Ngovan P; Simonpoli AM; Le Hoang P Ann Med Interne (Paris); 1988; 139(7):511-5. PubMed ID: 2854380 [No Abstract] [Full Text] [Related]
13. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671 [TBL] [Abstract][Full Text] [Related]
14. [Prevention and treatment of cytomegalovirus infections after graft of allogenic bone marrow]. Gluckman E; McMazeron ; Keable H; Meletis J; Bombail D; Jolivet I; Huart JJ; Nebout T; Cavazzana M; De Castro H Nouv Rev Fr Hematol (1978); 1987; 29(1):17-21. PubMed ID: 3035485 [TBL] [Abstract][Full Text] [Related]
15. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394 [TBL] [Abstract][Full Text] [Related]
16. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790 [TBL] [Abstract][Full Text] [Related]